Lyell Immunopharma Inc (LYEL)

Jan 9, 2025, 9:00 AM EST - 8 days ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 5 weeks ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 2 months ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 2 months ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 3 months ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 3 months ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 3 months ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 28, 2024, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 7, 2024, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 7 months ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 3, 2024, 4:05 PM EDT - 8 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 7, 2024, 4:05 PM EDT - 9 months ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 9 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 9 months ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 11 months ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 11 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 26, 2024, 4:05 PM EST - 11 months ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Jan 3, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 1 year ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 1 year ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

May 4, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 2, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Jan 3, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022, 7:00 AM EST - 2 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 1, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Nov 10, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 8, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Nov 7, 2022, 8:05 AM EST - 2 years ago

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Oct 6, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Oct 5, 2022, 8:05 AM EDT - 2 years ago

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 28, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Sep 12, 2022, 3:00 AM EDT - 2 years ago

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Aug 30, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

Aug 4, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

Jun 7, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

May 2, 2022, 4:30 PM EDT - 2 years ago

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

Mar 29, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 4:45 PM EST - 3 years ago

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Feb 17, 2022, 4:38 PM EST - 3 years ago

Biotech IPOs Have Slowed to a Snail's Pace

SANA

Jan 31, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

Jan 24, 2022, 12:39 PM EST - 3 years ago

FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors